Hyperion Therapeutics to Present at the Jefferies 2013 London Healthcare Conference

Hyperion Therapeutics to Present at the Jefferies 2013 London Healthcare
Conference

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2013 (GLOBE NEWSWIRE) -- Hyperion
Therapeutics (Nasdaq:HPTX) announced today that the company is scheduled to
present at the Jefferies 2013 London Healthcare Conference on Wednesday,
November 20 at 9:20 a.m. GMT.

Donald J. Santel, chief executive officer will provide a company overview. To
access the live webcast and subsequent archived recording, please visit
Hyperion's website at http://investors.hyperiontx.com/events.cfm.

About Hyperion Therapeutics

Hyperion Therapeutics, Inc. is a commercial stage biopharmaceutical company
committed to developing and delivering life-changing treatments for orphan
diseases and hepatology. The company's first commercial product, RAVICTI®
(glycerol phenylbutyrate) Oral Liquid, was approved in February 2013 and is
currently being marketed in the United States. The company also owns worldwide
rights to BUPHENYL® (sodium phenylbutyrate) Tablets and Powder, which it
markets in the U.S. The compound is also marketed internationally through
business partners. For more information, please visit www.hyperiontx.com.

CONTACT: Sylvia Wheeler, Investor Relations
         (650) 745-7834
         sylvia.wheeler@hyperiontx.com
 
Press spacebar to pause and continue. Press esc to stop.